Illumina, the leader in DNA sequencing technology, announced the creation of a new business unit called "BioInsight" on October 1, 2025. This move marks a strategic shift for the company from a supplier of genomics research equipment to a provider of comprehensive analytics and AI solutions. The BioInsight division will focus on developing software platforms and AI tools for the analysis of multi-omics data—that is, the integrated analysis of genomics, proteomics, metabolomics, and more. The new units target audience is pharmaceutical companies and biotech startups. By providing them with tools to analyze vast arrays of biological data, Illumina aims to accelerate the processes of discovering new drug targets and developing therapeutics, thereby taking on a more significant role in the biomedical industrys value chain.
Illumina Launches BioInsight Division for AI-Powered Multi-omics Analysis
